ProCE Banner Activity

SONIA: Phase III Trial Assessing the Optimal Therapeutic Position of CDK4/6 Inhibitors for Patients With HR+/HER2- Advanced Breast Cancer

Conference Coverage
Slideset

There was no PFS2 or OS benefit to adding CDK4/6i to endocrine therapy in the first-line vs second-line setting for women with HR+/HER2- advanced breast cancer.

Released: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo

Gilead

Merck Sharp & Dohme Corp.